Cardioembolic stroke related to atrial fibrillation is problematic due to high recurrence, mortality, and morbidity rates. The optimal anticoagulant therapy therefore needs to be applied to prevent the occurrence of a second stroke in patients with nonvalvular atrial fibrillation. The oral anticoagulant warfarin has traditionally been used, but it is limited by its narrow efficacy window, complex pharmacokinetics, and multiple drug interactions, thus requiring frequent blood monitoring. New oral anticoagulants have recently been developed that target a specific coagulation component. Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (inhibitors of factor Xa) have advantages of rapid action time, short half-life, stable plasma concentration, and few drug interactions. Large randomized clinical trials and meta-analyses have recently been published on the efficacy and safety of these new oral anticoagulants. Based on the results obtained in recent clinical trials, we have revised the recommendations for selecting optimal anticoagulant therapy in patients with nonvalvular atrial fibrillation.
Warfarin treatment (INR 2.0 -3.0) is recommended, unless contraindicated, in patients with ischemic stroke or TIA coexisting with sustained or paroxysmal AF (Evidence level: Ia, Recommendation grade: A).
2 If anticoagulants cannot be used, aspirin can be used instead (Evidence level: Ia, Recommendation grade: A) 3 A recommended daily dose of aspirin is 325mg. In Korea, a prescribable dose of 300mg may be considered (Evidence level: IV, Recommendation grade: GPP).
4
For the recurrence of ischemic stroke or TIA in the AF patients already receiving adequate anticoagulation therapy, increasing the therapeutic target to INR 2.5-3.5 or initiating a combination with antiplatelet agents may be considered (Evidence level: IV, Recommendation grade: C).
INR; international normalized ratio, TIA; transient ischemic attack, AF; atrial fibrillation, GPP; good practice point. 
GPP (Good practice points)
Recommended best practice based on the clinical experience of the guideline development group.
GPP; good practice point.
Policy and Research에서 제안한 방식에 기반을 두었다( Table 2) . 
Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY) 5 Table 3) .
RE-LY
새로운 근거와 권고수준 결정 배경 
